96950 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans Cytokines; Lymphokines; Interferons
Methods of using cytokine zalpha11 ligand
#902CYTOKINE ZALPHA11 LIGAND FUSION PROTEINS
#903Interferon-like protein ZCYTO21
#904Human zven polynucleotides
#905CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#906CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#907CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#908CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#909CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#910Growth factor homolog ZVEGF4
#911Growth factor homolog zvegf4
#912Method of using Zven antibodies
#913Methods for promoting growth of bone, ligament, and cartilage
#914Method of treating fibroproliferative disorders
#915METHOD OF REDUCING PROLIFERATION OF CELLS IN A MAMMAL
#916Cytokine zalpha11 ligand fusion proteins
#917Method of use of cytokine ZALPHA11 ligand
#918CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#919CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#920INTERFERON-LIKE PROTEIN ZCYTO21
#921Methods of using Zven proteins
#922Nucleic acid encoding a human allelic variant of interferon-like protein ZCYTO21
#923Methods of using Zven polynucleotides
#924CYTOKINE ZALPHA11 LIGAND ANTIBODIES
#925VEGF-related protein
#926Polypeptides homologous to VEGF and BMP1
#927Crystalline Neutrokine-alpha protein, method of preparation thereof, and method of use thereof
#928Interleukin-8 homologous polypeptides and therapeutic uses thereof
#929Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor
#930Adiponectin variants
#931Cytokine zalpha11 ligand antibodies
#932OX40R binding agents
#933Methods and compositions for regulating T cell subsets by modulating transcription factor activity
#934Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
#935Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
#936Method of screening for inhibitors of osteopontin
#937MDA-7 protein variants having antiproliferative activity
#938MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10
#939MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10
#940Mammalian cytokine-like polypeptide-10
#941VEGF variants
#942Neuronally expressed stem cell factor modulates angiogenesis and neural stem cell migration to areas of brain injury
#943Regulation of endogenous gene expression in cells using zinc finger proteins
#944Therapeutic agents comprising pro-apoptotic proteins
#945Trimeric OX40-immunoglobulin fusion protein and methods of use
#946Repressing endogenous CCR5 gene expression in cells using engineered zinc finger proteins
#947Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
#948Drug-eluting intravascular prostheses and methods of use
#949Vascular endothelial cell growth factor variants and uses thereof
#950T cell protein and nucleotides encoding the same
#951Vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis
#952Osteopontin-based cancer therapies
#953Ocular gene therapy
#954Chimeric IL-10
#955Process for bacterial production of polypeptides
#956Expression of mammalian proteins in
#957Isolating cells expressing secreted proteins
#958Polymer-modified synthetic proteins
#959Human TSLP polynucleotides
#960Feline interferon-alpha proteins
#961Interleukin-8 homologous polypeptides and therapeutic uses thereof
#962Cytokine polypeptides and antibodies containing a signal sequence for the attachment of glycosylphosphatidylinositol
#963IL-I7 homologous polypeptides and therapeutic uses thereof
#964Methods of treatment using antibodies to Neutrokine-alpha
#965Methods of Treatment Using Antibodies to Neutrokine-alpha
#966Method for preparing anti-MIF antibodies
#967Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
#968Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
#969Chimeric nucleic acids encoding polypeptides comprising CD154 and TNF-α
#970EphB receptor-binding peptides
#971Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use
#972Nucleic acid sequences encoding VEGF-like factors and uses thereof
#973Vegf peptides and their use
#974Inhibitor and stimulator of stem cell proliferation and uses thereof
#975Deletion forms of IGE-dependent histamine releasing factor having histamine releasing activity, HRF-binding peptides and the uses thereof
#976Method, compositions and classification for tumor diagnostics and treatment
#977Antibodies to natural killer cell activating factor II
#978Stem cells for use in locating and targeting tumor cells
#979Methods of treatment with an antibody that suppresses growth differentiation factor-14 activity
#980Chimeric protein
#981Proteolysis resistant active VEGF
#982Cytokine zcytor17 ligand polynucleotides
#983Apo-2 ligand/trail variants and uses thereof
#984New peptides
#985Cytokine designated 4-1BB ligand and human receptor that binds thereto
#986Compositions and methods for inducing gene expression
#987VEGF-related protein
#988Use of cardiotrophin to modulate stem cell proliferation
#989Human SDF-5 protein and compositions
#990Use of SDF-1 or G-CSF to improve myocardial function after ischemic injury
#991Cytokine designated 4-1BB ligand and human receptor that binds thereto
#992Human and murine cytokine polypeptides
#993Immunogenic conjugates
#994Osteopontin-coated surfaces and methods of use
#995Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
#996Treatment of inflammatory bowel disease using growth factors
#997Inflammatory mediator antagonists
#998Peptides that bind to the heparin binding domian of vegf and vegfr-2
#999Angiogenic factor and use thereof in treating cardiovascular disease
#1000Novel chemokine-like polypeptides
#1001Regulation of endogenous gene expression in cells using zinc finger proteins
#1002Highly hypoxia-specific gene expression system for ischemic gene therapy
#1003Chemotactic cytokine III
#1004Uses of agonists and antagonists to modulate activity of TNF-related molecules
#1005Endothelial-monocyte activating polypeptide III
#1006Natural killer cell activating factor II
#1007Vascular endothelial cell growth factor variants and uses thereof
#1008Antibodies that immunospecifically bind to B lymphocyte stimulator protein
#1009Method for determining MIF content
#1010Gene transcription and ionizing radiation: methods and compositions
#1011Vascular endothelial growth factor 2
#1012Expression of mammalian proteins in
#1013Methods of using human receptor protein 4-1BB
#1014Endothelial cell growth factor methods of isolation and expression
#1015Mammalian cell surface antigens; related reagents
#1016Variants of vascular endothelial cell growth factor, their uses, and processes for their production
#1017Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
#1018Methods for use of MPL ligands with primitive human stem cells
#1019Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
#1020Interleukin-8 homologous polypeptides and therapeutic uses thereof
#1021Thrombopoietin protein variants
#1022Methods of treatment using human tumor necrosis factor receptor TR17 antibodies
#1023Recombinant anti-osteopontin antibody and use thereof
#1024Receptor and related products and methods
#1025Antibodies to human vascular endothelial growth factor 2 and methods of using the same
#1026Methods of using IMXP-888 and IMXP-888 antagonists
#1027T cell activation
#1028Regulation of angiogenesis with zinc finger proteins
#1029Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
#1030Polynucleotides encoding mammalian cytokine-like factor 7
#1031Purified mammalian CTLA-8 antigens and related reagents
#1032Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
#1033Use of VEGF-D gene to prevent restenosis
#1034Vascular endothelial growth factor 2
#1035Antibodies that immunospecifically bind to B lymphocyte stimulator
#1036WNT-regulated cytokine-like polypeptide and nucleic acids encoding same
#1037Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
#1038Chimeric VEGF peptides
#1039Cytokine polypeptides
#1040Cysteine substitution variants of beta interferon
#1041Cysteine-containing peptide tag for site-specific conjugation of proteins
#1042Modified human interferon polypeptides and their uses
#1043Regulation of endogenous gene expression in cells using zinc finger proteins
#1044Human zven proteins
#1045Mammalian secreted proteins
#1046COOH-terminally added cysteine variant of the beta interferon
#1047Medical treatment
#1048Isolation, selection and propagation of animal transgenic stem cells
#1049Methods for diagnosing and treating bladder cancer
#1050Novel polynucleotides and proteins encoded thereby
#1051Method of treating hepatocellular carcinoma
#1052Cystine-knot fold protein
#1053Neutrokine-alpha fusion proteins
#1054Isolating cells expressing secreted proteins
#1055Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
#1056Venom-derived vascular endothelial growth factor-like protein having binding activity specific to vascular endothelial growth factor receptor type 2 and use thereof
#1057Process for producing physiologically active protein using genetically modified silkworm
#1058Use of osteopontin for the treatment and/or prevention of neurologic diseases
#1059Vascular endothelial growth factor 2
#1060Populations of cells that express flk-2 receptors
#1061Active antiangiogenic therapy
#1062Growth factor polypeptides and nucleic acids encoding same
#1063Preventives/remedies for bone/joint diseases
#1064Human growth hormone modified at position 35
#1065Growth factor homolog zvegf4
#1066Methods of preventing and treating inflammatory bowel disease
#1067Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides
#1068Preparing an implant by gas-plasma treatment of a substrate to couple cells
#1069Growth factor homolog zvegf3 polynucleotides
#1070Targeted drug delivery using EphA2 or EphA4 binding moieties
#1071Alternatively spliced nucleic acid molecules
#1072Vascular endothelial growth factor-x
#1073Methods of using human Zven proteins
#1074Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
#1075Mammalian cytokine-like factor 7
#1076Regulation of endogenous gene expression in cells using zinc finger proteins
#1077Secreted and transmembrane polypeptides and nucleic acids encoding the same
#1078Heterologous polypeptide of the TNF family
#1079Tango 240 nucleic acids and uses thereof
#1080Modified peptides as therapeutic agents
#1081Antibody conjugate methods for selectively inhibiting VEGF
#1082Osteopontin-related compositions and methods
#1083Vascular endothelial growth factor dimers
#1084Use of SARP-1 for the treatment and/or prevention of scleroderma
#1085Novel VEGF-like factor
#1086Secreted protein
#1087Compositions and methods for treating inflammatory disorders
#1088Cysteine variants of erythropoietin
#1089Interferon-like protein Zcyto21
#1090Interferon-like protein Zcyto21
#1091Leptin proteins
#1092Ligands for EPH-like receptors
#1093KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#1094Cysteine variants of erythropoietin
#1095Oligomeric molecules and uses thereof
#1096Anti-viral VSF protein and hybridoma producing the same
#1097Fusions of cytokines and tumor targeting proteins
#1098Human chemotactic cytokine I polypeptides
#1099EG-VEGF nucleic acids and polypeptides and methods of use
#1100Processed vascular endothelial growth factor-B polypeptides
#1101Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
#1102Vascular endothelial growth factor 2
#1103Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
#1104Chimeric IL-10 proteins and uses thereof
#1105VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
#1106Method for treating fibrosis
#1107Endothelial-monocyte activating polypeptide III antibodies
#1108Biosynthetic oncolytic molecules and uses therefor
#1109Defective recombinant adenoviruses expressing cytokines for antitumor treatment
#1110Use of VEGF-C or VEGF-D in reconstructive surgery
#1111Inhibitor of stem cell proliferation and uses thereof
#1112Secreted proteins
#1113Cardiotrophin-1 compositions and methods for the treatment of tumor
#1114Platelet derived growth factor (PDGF) nucleic acid ligand complexes
#1115Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
#1116Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
#1117Heparin binding VEGFR-3 ligands
#1118Methods for promoting growth of bone, ligament, and cartilage using zvegf4
#1119Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
#1120Isolation and mobilization of stem cells expressing vegfr-1
#1121Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
#1122Interferon-like protein Zcyto21
#1123Tango 240 polypeptides and uses thereof
#1124EphA4 Antibodies
#1125Organotypically cultured skin tissue comprising NIKS cells that express exogenous HIF-1a
#1126Pseudotyped lentiviral vectors and uses thereof
#1127Secreted proteins and polynucleotides encoding them
#1128Polypeptide, cDNA encoding the same, and use of them
#1129Monoclonal blocking antibody to human RANKL
#1130Populations of cells that express FLK-1 receptors
#1131Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)